New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
10:43 EDTATML, HLT, MTGE, AVNR, PPG, CLSN, OREX, END, AMKR, ACHNHigh option volume stocks
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
08:03 EDTCLSNCelsion reports FY15-end cash position of $20.1M
Subscribe for More Information
08:02 EDTCLSNCelsion highlights recent pipeline developments for GEN-1 program
Celsion highlighted recent accomplishments related to the Company's GEN-1 immunotherapy pipeline and provided a general business update. Celsion also announced the completion of enrollment of the first cohort of patients in its Phase 1b dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed ovarian cancer patients who will undergo neoadjuvant chemotherapy followed by surgical resection of their tumor. The first two patients in the OVATION Study who completed treatment have shown promising results. Both patients reported stable disease with a dramatic drop in their CA-125 protein levels of 89% and 98%. Cancer antigen 125 is used to monitor certain cancers during and after treatment. A 50% reduction in CA-125 levels is considered meaningful. Both patients' CA-125 levels were below the normal healthy level of 35 U/mL. In addition, both patients experienced successful surgical resections of their tumors with one patient reporting a R0 resection which indicates a microscopically margin-negative resection in which no gross or microscopic tumor remains in the tumor bed. The OVATION Study will continue into 2016 at higher doses of GEN-1 with the goal to identify a safe, tolerable and therapeutically active dose of GEN-1 by recruiting and maximizing an immune response. Celsion has initiated four clinical sites at the University of Alabama at Birmingham; Oklahoma University Medical Center; Washington University in St. Louis and the Medical College of Wisconsin. The trial is designed to enroll three to six patients per dose cohort and will evaluate safety and efficacy and attempt to define an optimal dose for a follow-on Phase I/II study combining GEN-1 with Avastin and Doxil. The company has completed various preclinical studies combining GEN-1 with Avastin and Doxil, the current standard of care for the treatment of platinum resistant ovarian cancer, which has demonstrated synergistic anti-cancer effects.
February 11, 2016
16:21 EDTAMKRAmkor Technology sees FY16 CapEx $650M
Subscribe for More Information
16:20 EDTAMKRAmkor Technology sees Q1 EPS (15c)-(3c), consensus
Subscribe for More Information
16:19 EDTAMKRAmkor Technology reports Q4 non-GAAP EPS 2c, consensus 3c
Subscribe for More Information
07:17 EDTOREX, ACHNLeerink to hold a conference
Subscribe for More Information
06:24 EDTACHNAchillion initiates Phase 1 study of ACH-4471
Subscribe for More Information
February 10, 2016
11:19 EDTMTGEPine River Capital reports 5.3% passive stake in American Capital Mortgage
Subscribe for More Information
February 4, 2016
07:07 EDTAMKRHMG Strategy is holding a summit
2016 Phoenix CIO Executive Leadership Summit is being held in Scottsdale, AZ on February 4.
07:00 EDTATMLSilicon Laboratories an attractive acquisition target, says Citi
Citi analyst Atif Malik calls Silicon Laboratories (SLAB) an attractive acquisition target after the company beat Q4 earnings expectations. He contends Silicon would garner a 15% premium to peer Atmel's (ATML) takeout price. If Atmel is worth $8.15 per share, Silicon Laboratories is worth $50, Malik tells investors in a post-earnings research note. He lowered his price target for Silicon to $50 from $58 and keeps a Buy rating on the name.
February 3, 2016
16:04 EDTMTGEAmerican Capital Mortgage reports Q4 EPS (13c) vs. (49c) last quarter
Subscribe for More Information
February 1, 2016
12:48 EDTHLTOptions with increasing call volume
Subscribe for More Information
10:08 EDTHLTHigh option volume stocks
High option volume stocks: NOK HLT NCLH DF GALE VMW DPS SYY SYMC PGR

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use